Immunologic Risk of Pregnancy in Women With Lung Transplantion : a National Multicentric Study

Launched by NANTES UNIVERSITY HOSPITAL · Jan 16, 2023

Keywords

ClinConnect Summary

This clinical trial, called TRIGGER 2, is studying the immunological risks associated with pregnancy in women who have received lung transplants. The goal is to understand how having a child might affect the mother's immune system, specifically looking at a type of immune response known as humoral rejection, which can occur if the mother and her child share certain genetic markers (HLA antigens) with the lung donor. By evaluating the genetic information from both the mother and her child, researchers hope to develop recommendations to help minimize any potential risks for women with lung transplants who become pregnant.

Eligible participants for this study include children born between January 1, 2012, and December 31, 2021, to women over the age of 18 who have had lung transplants in France and are currently alive. Parents or legal guardians will need to give their consent for the study, which involves a simple oral swab to gather genetic information. If you choose to participate, your child’s information will be compared with that of the mother and the lung donor to better understand the risks involved. This study aims to provide valuable insights to help ensure safer pregnancies for women with lung transplants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children born between 01/01/2012 and 31/12/2021 of female patients over 18 years old with lung transplantation (mono, uni or cardio pulmonary) in France,
• • Alive at the time of our study.
• • Legal guardians' consent for oral swabbing of their child and HLA typing on this swab
• • Affiliated or beneficiaries of a social security system or similar
• Exclusion Criteria:
• • - Refusal of consent by the patient and/or one of the two parents